Jennifer English

Chief of Staff for Value & Access - Head of Strategic Pricing, Marketing & Operations at Ipsen

Speaker

Jen English is the Chief of Staff for Value & Access and Head of Strategic Pricing, Marketing & Operations at Ipsen US. She is responsible for defining the current and future market access capabilities required to support Ipsen’s portfolio, based on the ever-evolving U.S. healthcare landscape, focused on changes to legal/regulatory reform, customer economics, market evolution and business innovation. She drives the implementation, execution and measurement of Ipsen V&A strategies to increase access for patients, while optimizing revenue for the current and future US portfolio to ensure Ipsen’s long term competitive success.

Jen acts as the primary business unit lead with all cross-functional partners, including the brand teams. In driving strategy, pricing, marketing and operational excellence, she enables optimal performance by identifying, exploring and driving capabilities (processes, tools and competencies). She also serves as the US V&A lead working with her team on licensing & acquisition activities.

Jen has been in the pharmaceutical industry since 1996 and entered the world of Managed Markets in 2000. She has established herself as a subject matter expert in market access strategy, contract operations, gross-to-net forecasting, government program price reporting and compliance. She has also led the order to cash process, including Customer Service, Chargebacks, Rebates, Government Price Reporting and Accounts Receivable. Jen has supported two company’s in launching their first commercial products by establishing the pricing and contract strategy, pricing committee structure, commercial and government contract operations and the government price reporting programs. Her uniquely situated role enabled her to oversee gross-to-net forecasting and provide analytical contributions to the Board, Global Product Teams, Finance, Sales, Marketing and Market Access departments. Jen has held positions of increasing responsibility at: Insmed, Acorda Therapeutics, Aptalis Pharma, Optimer Inc. and Nycomed US Inc. She began her biopharma career at Bristol-Myers Squibb Company.

Jen has a BA in History/Political Science from Rutgers University, a Post-BA Paralegal Certificate from Montclair State University, and an MBA from Rutgers Graduate School of Management. She is a frequent speaker at Government Pricing, Contracting and Gross-to-Net conferences. Additionally, she is a guest lecturer for the Rutgers MBA Pharmaceutical Program, sharing her subject matter knowledge on the US pharmaceutical pricing, payer and grossto-net landscape each semeste